Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
47.85
+1.30 (2.79%)
At close: Aug 13, 2025, 4:00 PM
47.79
-0.06 (-0.13%)
Pre-market: Aug 14, 2025, 9:11 AM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.27B in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
2.04
Revenue / Employee
$1,398,944
Employees
34,100
Market Cap
97.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BMY News
- 6 days ago - 3 SWANs On Sale - Seeking Alpha
- 9 days ago - Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity - Seeking Alpha
- 9 days ago - Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Business Wire
- 10 days ago - Bristol-Myers Squibb: Buy The Weakness - Seeking Alpha
- 11 days ago - Bristol-Myers Squibb: Declines Have Gone Too Far - Seeking Alpha
- 12 days ago - Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields - Seeking Alpha
- 12 days ago - Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline - Seeking Alpha
- 12 days ago - Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade) - Seeking Alpha